NISSAN CHEMICAL INDUSTRIES, TEIJIN PHARMA TO COLLABORATE IN DEVELOPING DRUG CANDIDATE
Nissan Chemical Industries and Teijin Pharma jointly have reached a basic agreement to collaborate in developing a drug candidate discovered by the former. Specifically, the two companies aim to develop an agent for the treatment of atrial fibrillation and flutter. They plan to start a Phase I clinical trial in 2007. Further details are to be finalized later on.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10660)